Concern In Argentina Over Trade Secrets

25 November 1996

The Argentine government is debating proposals for the introduction of a Trade Secrets Act, which the national pharmaceutical industry association, Cilfa, fears could be detrimental to its interests.

Alberto Schilling, representing Cilfa and ALIFAR, the Latin American pharmaceutical industry organization (Marketletters passim), at an international conference on intellectual property in India (see pages 17, 24 and 25), told the Marketletter that Cilfa is concerned about a number of issues relating to the bill.

The organization fears that the bill may be an indirect way of implementing a pipeline clause and retroactivity in relation to intellectual property. Argentina introduced a new patent law in 1995 which does not contain these features (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight